Microcap Ledger Nuvectis Pharma, Inc. $NVCT
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Fort Lee, NJ
- Fiscal year end
- December 31
- Shares outstanding
- 32,581,533 [10-Q 2026-08-04]
What the company doesAI summary of filing
Nuvectis Pharma is a clinical-stage biopharmaceutical company developing precision medicines for oncology. The company is focused primarily on NXP900, a small molecule inhibitor of SRC and YES1 kinases for solid tumors, which completed Phase 1a dosing in July 2025 and initiated Phase 1b expansion in August 2025. The company also holds rights to NXP800, a product candidate for which it ceased clinical development in July 2025. Nuvectis has not generated revenue and is pre-revenue, funding operations through capital raises while advancing NXP900 through clinical trials toward potential regulatory approval. [10-K 2026-02-11]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$13.07M | −$11.04M | $22.16M | [10-Q 2026-08-04] |
| FY ended Dec 2025 | — | −$26.44M | −$16.01M | $31.63M | [10-K 2026-02-11] |
| FY ended Dec 2024 | — | −$19.00M | −$12.25M | $18.53M | [10-K 2026-02-11] |
- Quarterly cash burn
- −$5.52M
- Cash runway Estimate
- ~12 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 19,320,973 | [10-Q 2024-11-05] |
| 2025-02-21 | 23,391,499 | [10-K 2025-02-25] |
| 2025-05-01 | 23,634,586 | [10-Q 2025-05-06] |
| 2025-08-01 | 25,456,848 | [10-Q 2025-08-05] |
| 2025-11-01 | 25,614,896 | [10-Q 2025-11-04] |
| 2026-02-06 | 26,491,702 | [10-K 2026-02-11] |
| 2026-05-01 | 26,525,533 | [10-Q 2026-05-05] |
| 2026-07-31 | 32,581,533 | [10-Q 2026-08-04] |
- Shelf registration
- S-3 filed 2026-08-21; declared effective 2026-08-28 [S-3 2026-08-21]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-03 | Carson Michael J. | grant | 30,000 | — | [4 2026-08-05] |
| 2026-06-30 | Mosseri Marlio Charles | buy | 50,000 | $18.32 | [4 2026-07-01] |
| 2026-06-30 | Bentsur Ron | buy | 12,500 | $20.00 | [4 2026-07-01] |
| 2026-06-11 | Hoberman Kenneth | grant | 35,000 | — | [4 2026-06-12] |
| 2026-06-11 | Oliviero James F Iii | grant | 35,000 | — | [4 2026-06-12] |
| 2026-06-11 | Sanchez Juan | grant | 35,000 | — | [4 2026-06-12] |
| 2026-06-11 | Kaplan Matthew L. | grant | 35,000 | — | [4 2026-06-12] |
| 2026-01-06 | Shemesh Shay | grant | 150,000 | — | [4 2026-01-09] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-21 | S-3 | Registration statement |
| 2026-08-21 | 8-K | Other events |
| 2026-08-06 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-04 | 10-Q | Quarterly report |
| 2026-08-04 | 8-K | Results of operations |
| 2026-06-30 | 8-K | Material agreement entered; Other events |
| 2026-06-30 | 424B5 | Prospectus or prospectus supplement |
| 2026-06-29 | 424B5 | Prospectus or prospectus supplement |
| 2026-06-29 | 8-K | Other events |
| 2026-06-23 | 8-K | Material agreement entered; Other events |
| 2026-06-12 | 8-K | Shareholder vote results |
| 2026-05-05 | 10-Q | Quarterly report |
Alerts for $NVCT
Email me when Nuvectis Pharma, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.